A Vancouver-based biotechnology firm this month revealed a strategic investment to improve clinical therapeutics. Acuitas Therapeutics, a developer of lipid nanoparticle delivery systems for nucleic acid therapeutics, has acquired a majority stake in Montreal’s RNA Technologies & Therapeutics, a company specializing in the design and manufacturing of RNA constructs. “As genetic medicines expand into more […]